The present invention provides effective and safe medicaments for thetreatment of connective tissue diseases of the skin, particularly with respectto the treatment of cutaneous forms of Lupus Erythematous. The medicamentscomprise as the therapeutically active ingredient a beta2 adrenoceptoragonist. The invention furthermore relates to dermatological compositionswithout skin sensitization properties and which contain enantiomerically pureor enriched R-enantiomers of a beta2 adrenoceptor agonist.